EyePoint Pharmaceuticals, Inc. hit the mark in a Phase II trial testing its primary pipeline asset, EYP-1901, as a maintenance treatment for wet age-related macular degeneration with the potential for dosing just twice a year. The company’s stock price surged on the announcement on 4 December to open 232% higher at $22.
EyePoint Hits New Durability Milestone For Wet AMD Treatment
Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.
More from Sensory
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.